CN1686182A - 补充钙镁和维生素d的药品制剂 - Google Patents
补充钙镁和维生素d的药品制剂 Download PDFInfo
- Publication number
- CN1686182A CN1686182A CNA2005100557478A CN200510055747A CN1686182A CN 1686182 A CN1686182 A CN 1686182A CN A2005100557478 A CNA2005100557478 A CN A2005100557478A CN 200510055747 A CN200510055747 A CN 200510055747A CN 1686182 A CN1686182 A CN 1686182A
- Authority
- CN
- China
- Prior art keywords
- calcium
- magnesium
- vitamin
- medicine preparation
- additional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 239000011575 calcium Substances 0.000 title claims abstract description 76
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 76
- 229930003316 Vitamin D Natural products 0.000 title claims abstract description 42
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 42
- 239000011710 vitamin D Substances 0.000 title claims abstract description 42
- 235000019166 vitamin D Nutrition 0.000 title claims abstract description 42
- 150000003710 vitamin D derivatives Chemical class 0.000 title claims abstract description 42
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 42
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000011777 magnesium Substances 0.000 title claims abstract description 26
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 26
- 230000001502 supplementing effect Effects 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229960005069 calcium Drugs 0.000 claims description 71
- 239000003814 drug Substances 0.000 claims description 21
- 229940091250 magnesium supplement Drugs 0.000 claims description 21
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 13
- 239000000395 magnesium oxide Substances 0.000 claims description 13
- 235000012245 magnesium oxide Nutrition 0.000 claims description 13
- 239000007968 orange flavor Substances 0.000 claims description 13
- 229940013618 stevioside Drugs 0.000 claims description 13
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 13
- 235000019202 steviosides Nutrition 0.000 claims description 13
- 229960000869 magnesium oxide Drugs 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 8
- 229960003563 calcium carbonate Drugs 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960002713 calcium chloride Drugs 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- 239000004227 calcium gluconate Substances 0.000 claims description 3
- 235000013927 calcium gluconate Nutrition 0.000 claims description 3
- 229960004494 calcium gluconate Drugs 0.000 claims description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 229960002337 magnesium chloride Drugs 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- 108010033929 calcium caseinate Proteins 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000001362 calcium malate Substances 0.000 claims description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 2
- 229940016114 calcium malate Drugs 0.000 claims description 2
- 235000011038 calcium malates Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960001708 magnesium carbonate Drugs 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 2
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 2
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 2
- 239000000626 magnesium lactate Substances 0.000 claims description 2
- 235000015229 magnesium lactate Nutrition 0.000 claims description 2
- 229960004658 magnesium lactate Drugs 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 239000004137 magnesium phosphate Substances 0.000 claims description 2
- 229960002261 magnesium phosphate Drugs 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 206010006956 Calcium deficiency Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000003076 Osteolysis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种补充钙镁和维生素D的药品制剂，主要含有钙剂、镁剂及维生素D，每100g补充钙镁和维生素D的药品制剂中含有：钙元素17－23g、镁元素8.5－11.5g、维生素D 57IU－77IU。本发明的补充钙镁和维生素D的药品制剂具有吸收和转化效果好、成本低、无副作用的优点。
Description
技术领域
本发明涉及一种补钙药品，用于儿童、青少年、妊娠、哺乳妇女、更年期妇女、中老年人等的钙补充剂，也用于预防骨质疏松症。
背景技术
钙是人体必需的矿物质，99％存在于骨骼和牙齿中，其中1％的钙分布在软组织和细胞外液中。钙不仅构成了人体的骨架，而且对人体的神经、肌肉的应激冲动传递、心脏节律的维持、保持细胞膜的完整性和通透性、维持体内的酸碱平衡、血液的凝固都起着无法替代的重要作用，而且钙可降低毛细血管的通透性、防止渗出，控制炎症与水肿。
2000年，中国营养学会正式修订和通过了“中国居民膳食营养素参考摄入标准(DRIs)”。在这标准中，钙的每日推荐供给量为：18-49岁800mg；50岁以上1000mg。
我国90年代营养调查显示，我国属于低钙摄入的国家。我国居民每日钙平均摄入量500mg左右，不少省份低于400mg，此值不足生理供给量的50％，还远低于1990年中国营养学会修订的有关营养素膳食推荐量标准(RDA)中规定的成人每日800mg的标准；更低于西方一些国家每日摄入1000-1200mg的标准。
人体钙摄入不足，会影响身体发育，并可致多种疾病。孕妇严重缺钙则发生抽搐、妊高症等；中老年缺钙则会导致高血压、动脉硬化和关节腰腿痛；而最为普遍的发生的则是中老年人的骨质疏松综合症。钙的营养不足不仅是儿童，也成为中老年群体的重要营养问题。
人体所需要的钙主要来自于食物，我国是植物食物为主的传统膳食结构的国家，服乳制品较少。目前人们已意识到低钙摄入的危险性，不仅食物中钙补充受到广泛重视，钙剂在用于治疗的同时也开始用于缺钙的预防性补充。
钙的补充可分为针对缺钙人群的预防性补钙，针对与缺钙相关疾病有关联的特殊人群进行保健性补钙，针对疾病人群进行治疗性补钙。
然而，现有的钙剂也存在一些不足，主要表现在：在补钙过程中，特别是在保健性补钙和治疗性补钙中，一部分人会出现补钙效果不明显的问题，主要是人体对钙的吸收和转化利用效果不好。维生素D是重要钙调节激素之一，肠钙吸收和钙的吸收利用转化都离不开维生素D。为强化钙的吸收和转化，目前一些钙剂中也加入了维生素D，但因维生素D与钙剂在钙剂中的含量及比例不合理，仍然使钙的吸收和转化不理想。
发明内容
针对目前的钙剂存在的上述不足以及人们对钙摄入量的不足，本发明的目的在于提供一种易于吸收和转化、无不良反应且成本较低的补充钙镁和维生素D的药品制剂。
本发明提供的补充钙镁和维生素D的药品制剂，主要含有钙剂、镁剂及维生素D，每100g补充钙镁和维生素D的药品制剂中含有：钙元素17-23g、镁元素8.5-11.5g、维生素D 57IU-77IU。
作为一种优选的实施例，每100g补充钙镁和维生素D的药品制剂中含有钙元素20g、镁元素10g、维生素D67IU。
所述的钙剂可以为醋酸钙、碳酸钙、酪蛋白钙、氯化钙、柠檬酸钙、柠檬酸苹果酸钙、葡萄糖酸钙、乳酸钙、苹果酸钙、磷酸氢钙、磷酸二氢钙、磷酸钙、硫酸钙、抗坏血酸钙、甘油磷酸钙、生物钙等能够被人体吸收的含钙元素的产品中的一种或多种。
所述的所述的镁剂可以为氧化镁、碳酸镁、氯化镁、柠檬酸镁、葡萄糖酸镁、乳酸镁、磷酸氢镁、磷酸镁、甘油磷酸镁等能够被人体吸收的含镁元素的产品中的一种或多种。
所述的剂型可以为颗粒剂、片剂、粉剂、胶囊等现有的剂型。
所述剂型优选为片剂，其中辅料由适量的乳糖和甘露醇、甜菊糖、甜橙香精粉末、5％PVP-K30(吡咯烷酮)、硬脂酸镁组成。
所述的乳糖、甜菊糖、甜橙香精粉末在片剂中的最佳的重量含量分别为：乳糖10-12％、甜菊糖0.25-0.6％、甜橙香精粉末0.5-1％。
对于片剂，每片重量为1.5g，成人每日2片，分1-2次服用。儿童一日1片，一日一次。
对于其它剂型，每日的服用量可按上述片剂每天的钙摄入量标准服用。
这种补充钙镁和维生素D的药品制剂，适用于儿童、青少年、妊娠、哺乳妇女、更年期妇女、中老年人等的钙补充剂，也用于预防骨质疏松症。
本发明的补充钙镁和维生素D的药品制剂的有益效果是：
(1)本发明的补充钙镁和维生素D的药品制剂中，通过对维生素D与碳酸钙的用量进行科学合理的搭配，通过维生素D的促进钙在小肠内的吸收，而且使维生素D能够具有成骨和溶骨作用，在生理剂量下促进成骨，大剂量时依靠甲状旁腺腺素发挥溶骨作用，间接的调节血钙在正常范围，所以对钙的吸收和转化效果好。
(2)镁是人体必需的常量元素，是骨和齿的重要成分之一。补钙的关键在吸收，钙吸收受多种因素的影响，钙与镁的关系十分密切，镁缺乏则钙吸收不良，镁能够促进钙的吸收利用，还与镁一起催化、激活多种酶的活性，参与许多与骨代谢有关的生化反应，它是一个促进钙吸收的重要元素。没有足够的镁，钙不能充分吸收。镁在控制钙的摄入、含量、结合以及重新分布上有重要作用，镁的运输依赖钙泵，而钙的代谢依赖镁的调节，低镁时可增强钙的内向流，高镁时阻滞钙的内向流，故镁与钙必须平衡，补钙的同时也应补镁，防止低镁高钙。本发明的补充钙镁和维生素D的药品制剂，由于含有氧化镁，且钙与镁的用量合理，在补钙同时又补充了镁，能够恢复体内两种离子的平衡，特别是与维生素D共同作用，促进了钙的吸收和代谢，因此补钙效果好。
(3)镁对心血管具有明显的保护作用，因此本发明的补充钙镁和维生素D的药品制剂在补钙的同时可明显提高高密度脂蛋白水平，同时显著降低甘油三脂、胆固醇与低密度脂蛋白水平，从而有效地防治高脂血症及其继发的动脉粥样硬化，进而保护心脑器官。
(4)制成片剂，便于包装、储存及服用，加入合理的微晶纤维素，有利于崩解吸收。
(5)当采用片剂时，本发明还精选了乳糖、甜菊糖、甜橙香精粉末作为矫味剂，并通过三种矫味剂的合理搭配，使这种片剂口味好，特别适合于儿童补钙用。
具体实施方式
下面结合具体实施例对本发明补充钙镁和维生素D的药品制剂作进一步说明。
实施例1
将碳酸钙75g、氧化镁25g、维生素D100IU、微晶纤维素15g、乳糖17.3g、甘露醇15g、甜菊糖0.45g、甜橙香精粉末0.75g、硬脂酸镁1.5g及5％PVP-K30适量制成100片片剂。
实施例2
将氯化钙95g、氧化镁21.1g、维生素D115IU、微晶纤维素10g、乳糖10.2g、甘露醇11g、甜菊糖0.45g、甜橙香精粉末0.75g、硬脂酸镁1.5g及5％PVP-K30适量制成100片片剂。
实施例3
将氯化钙71.4g、葡萄糖酸钙16.1g、氧化镁28.6g、维生素D85IU、微晶纤维素10g、乳糖10.2g、甘露醇11g、甜菊糖0.45g、甜橙香精粉末0.75g、硬脂酸镁1.5g及5％PVP-K30适量制成100片片剂。
实施例4
将磷酸二氢钙40g、碳酸钙48.5g、氯化镁30g、碳酸镁30、硬脂酸镁1.5g，研细过筛，加入维生素D100IU混合均匀装胶囊。
实施例5
将碳酸钙75g、氧化镁25g、维生素D90IU、微晶纤维素15g、乳糖17g、甘露醇14.1g、甜菊糖0.9g、甜橙香精粉末0.75g、5％PVP-K30适量、硬脂酸镁1.5g制片，共制100片
实施例6
将碳酸钙75g、氧化镁25g、维生素D110IU、微晶纤维素15g、乳糖15g、甘露醇15g、甜菊糖1g、甜橙香精粉末2.5g、5％PVP-K30适量、硬脂酸镁1.5g，共制100片片剂
实施例7
将碳酸钙75g、氧化镁25g、维生素D100IU、微晶纤维素15g、乳糖16g、甘露醇15g、甜菊糖1g、甜橙香精粉末1.5g、5％PVP-K30适量、硬脂酸镁1.5g，制成100片片剂。
Claims (7)
1、一种补充钙镁和维生素D的药品制剂，主要含有钙剂、镁剂及维生素D，每100g补充钙镁和维生素D的药品制剂中含有：钙元素17-23g、镁元素8.5-11.5g、维生素D 57IU-77IU。
2、如权利要求1所述的补充钙镁和维生素D的药品制剂，其特征在于，每100g补充钙镁和维生素D的药品制剂中含有钙元素20g、镁元素10g、维生素D67IU。
3、如权利要求1或2所的补充钙镁和维生素D的药品制剂，其特征在于，所述的钙剂为醋酸钙、碳酸钙、酪蛋白钙、氯化钙、柠檬酸钙、柠檬酸苹果酸钙、葡萄糖酸钙、乳酸钙、苹果酸钙、磷酸氢钙、磷酸二氢钙、磷酸钙、硫酸钙、抗坏血酸钙、甘油磷酸钙、生物钙中的一种或多种。
4、如权利要求1或2所的补充钙镁和维生素D的药品制剂，其特征在于，所述的所述的镁剂为氧化镁、碳酸镁、氯化镁、柠檬酸镁、葡萄糖酸镁、乳酸镁、磷酸氢镁、磷酸镁、甘油磷酸镁中的一种或多种。
5、如权利要求1或2所述的补充钙镁和维生素D的药品制剂，其特征在于：该制剂为片剂或颗粒剂、胶囊。
6、如权利要求5所述的补充钙镁和维生素D的药品制剂，其特征在于：为片剂，其中辅料由适量的乳糖和甘露醇、甜菊糖、甜橙香精粉末、5％PVP-K30、硬脂酸镁组成。
7、如权利要求6所述的补充钙镁和维生素D的药品制剂，其特征在于，所述的乳糖、甜菊糖、甜橙香精粉末在片剂中的重量含量分别为：乳糖10-12％、甜菊糖0.25-0.6％、甜橙香精粉末0.5-1％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100557478A CN100515430C (zh) | 2005-03-21 | 2005-03-21 | 补充钙镁和维生素d的药品制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100557478A CN100515430C (zh) | 2005-03-21 | 2005-03-21 | 补充钙镁和维生素d的药品制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686182A true CN1686182A (zh) | 2005-10-26 |
| CN100515430C CN100515430C (zh) | 2009-07-22 |
Family
ID=35304224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100557478A Expired - Fee Related CN100515430C (zh) | 2005-03-21 | 2005-03-21 | 补充钙镁和维生素d的药品制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100515430C (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103796658A (zh) * | 2011-07-28 | 2014-05-14 | 加拿大生维达有限公司 | 含有高溶性元素和维生素并能预防和改善骨质疏松症的组合物 |
| CN105125579A (zh) * | 2015-09-10 | 2015-12-09 | 重庆布尔动物药业有限公司 | 钙镁维生素注射液 |
| CN105963318A (zh) * | 2016-05-03 | 2016-09-28 | 宣城柏维力生物工程有限公司 | 一种钙镁维d片及其制备方法 |
| CN106619705A (zh) * | 2016-12-02 | 2017-05-10 | 芜湖市诺康生物科技有限公司 | 一种钙镁加维生素d软胶囊及其制备方法 |
| CN106913856A (zh) * | 2017-04-07 | 2017-07-04 | 南通市第人民医院 | 一种动物专用钙片及其制备方法 |
| CN114431479A (zh) * | 2020-11-05 | 2022-05-06 | 浙江创新生物有限公司 | 钙镁维生素d咀嚼片及其制备方法 |
-
2005
- 2005-03-21 CN CNB2005100557478A patent/CN100515430C/zh not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103796658A (zh) * | 2011-07-28 | 2014-05-14 | 加拿大生维达有限公司 | 含有高溶性元素和维生素并能预防和改善骨质疏松症的组合物 |
| CN105125579A (zh) * | 2015-09-10 | 2015-12-09 | 重庆布尔动物药业有限公司 | 钙镁维生素注射液 |
| CN105963318A (zh) * | 2016-05-03 | 2016-09-28 | 宣城柏维力生物工程有限公司 | 一种钙镁维d片及其制备方法 |
| CN105963318B (zh) * | 2016-05-03 | 2018-12-14 | 宣城柏维力生物工程有限公司 | 一种钙镁维d片及其制备方法 |
| CN106619705A (zh) * | 2016-12-02 | 2017-05-10 | 芜湖市诺康生物科技有限公司 | 一种钙镁加维生素d软胶囊及其制备方法 |
| CN106913856A (zh) * | 2017-04-07 | 2017-07-04 | 南通市第人民医院 | 一种动物专用钙片及其制备方法 |
| CN114431479A (zh) * | 2020-11-05 | 2022-05-06 | 浙江创新生物有限公司 | 钙镁维生素d咀嚼片及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100515430C (zh) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8557299B2 (en) | Dietary supplement containing alkaline electrolyte butters | |
| CN100515430C (zh) | 补充钙镁和维生素d的药品制剂 | |
| CN1820647A (zh) | 一种增强记忆力的营养粉 | |
| CN112352955A (zh) | 一种基于生酮原理干预多囊卵巢综合症的低gi全营养代餐粉及其应用 | |
| CN101040710A (zh) | 一种内服调节女士内分泌兼外用美容养颜的保健营养冲剂 | |
| CN100515429C (zh) | 补充钙镁的药品制剂 | |
| CN110214942A (zh) | 一种甲亢专用型医学营养配方及其制备方法 | |
| CN110538315B (zh) | 一种具有防治透析患者并发症功效的组合物及其制备方法和其应用 | |
| KR20010066713A (ko) | 다이어트 인삼제품 제조방법 | |
| CN110214938A (zh) | 用于糖尿病人群的特殊医学用途配方营养粉及其制备方法 | |
| CN1679593A (zh) | 一种含有α－亚麻酸游离酸、大豆磷脂和维生素E的复合制剂 | |
| CN108125941A (zh) | 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用 | |
| CN104001157A (zh) | 一种防治骨质疏松症的复方制剂及其制备方法 | |
| CN107595829B (zh) | 一种防治肾性骨营养不良的组合物 | |
| JPH09238615A (ja) | 健康栄養食品 | |
| CN1431002A (zh) | 一种蜂胶降糖降脂保健组合物及其胶囊的制造方法 | |
| US9808441B2 (en) | Dietary supplement containing alkaline electrolyte buffers | |
| CN1305400C (zh) | 黑木耳燕麦羹及其制备方法 | |
| CN1883593A (zh) | 九味补血口服液 | |
| CN1064789A (zh) | 益寿养生粉 | |
| CN1557301A (zh) | 降低老年肥胖型糖尿病人血糖和血脂的组合物 | |
| CN106723022A (zh) | 一种梅花鹿茸蝙蝠蛾拟青霉菌胶囊及其制备方法 | |
| CN1050035C (zh) | 营养保健蜂蜜的生产方法 | |
| KR100584214B1 (ko) | 모려칼슘을 유효성분으로 하는 약효증진제의 제조방법 | |
| CN101204400A (zh) | 阿胶系列产品的配方和制造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN THEIL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENG GANG Effective date: 20080404 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080404 Address after: Liuyang City, Hunan Province, North Li Qiao bridge, Hunan, Changsha mailbox, code: 410011 Applicant after: Hunan Taier Pharmaceutical Company Limited Address before: Hunan province Changsha Shinan District South Road No. 179 post encoding: 410000 Applicant before: Cheng Gang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal preparation for supplementing calcium, magnesium and vitamin D Effective date of registration: 20150212 Granted publication date: 20090722 Pledgee: Bank of Beijing Limited by Share Ltd Changsha branch Pledgor: Hunan Taier Pharmaceutical Company Limited Registration number: 2015430000004 |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20161107 Granted publication date: 20090722 |
|
| RINS | Preservation of patent right or utility model and its discharge | ||
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20191107 Granted publication date: 20090722 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090722 Termination date: 20210321 |